All Oncology News

Roche Registration GmbH has withdrawn its application to extend the use of atezolizumab to the treatment of patients with early or locally advanced triple-negative breast cancer in Europe.

The FDA has granted priority review to a new drug application for the nanoparticle albumin-bound mTOR inhibitor nab-sirolimus for the treatment of patients with malignant perivascular epithelioid cell neoplasm.

The FDA has issued a complete response letter to Incyte Corporation stating that it cannot approve the biologics license application for retifanlimab for use in adult patients with locally advanced or metastatic squamous cell carcinoma of the anal canal who have progressed on, or who are intolerant of, platinum-based chemotherapy, in its present form.

The use of oncology biosimilars has expanded rapidly in the United States during the past 2 years as providers embraced a growing armamentarium of new products, according to findings from real-world data reported at the 2021 American Society of Clinical Oncology Annual Meeting.

Surgical resection demonstrated a notable survival benefit, particularly in combination with neoadjuvant therapy, in patients with aggressive margin-positive pancreatic cancer.

A multimodality approach to treatment, which included sequential chemotherapy and radiation therapy followed by surgery, resulted in successful resection for most patients with marginally inoperable soft tissue sarcomas.

The combination of brentuximab vedotin plus doxorubicin, vinblastine, and dacarbazine with and without consolidative radiotherapy was found to have strong efficacy and favorable tolerability in patients with early-stage, unfavorable-risk, Hodgkin lymphoma.

Bristol Myers Squibb has decided to voluntarily withdraw the indication for nivolumab as a monotherapy for patients with hepatocellular carcinoma who were previously treated with sorafenib from the US market.

Multicancer early detection tests yielded high specificity and accuracy in predicting cancer signal origin and identified cancer signals in multiple tumor types.

The CAR T-cell product tisagenlecleucel has been shown to elicit durable responses in adult patients with relapsed/refractory follicular lymphoma with a safety profile that compares favorably with other available products.

Brain imaging should be considered for patients with advanced or metastatic renal cell carcinoma who have a high metastatic burden and who have progressed after treatment with first-line therapies.

Heterogeneity in the cellular and molecular features of CAR T-cell products contributes to variation in efficacy and toxicity follow treatment with axicabtagene ciloleucel in patients with large B-cell lymphoma, and molecular response at day 7 might represent an early predictor of efficacy with this modality.

Rodolfo Gutierrez, MD, discusses racial disparities in cancer care and interventions to encourage increased participation of the Hispanic and Latinx community on clinical trials.

During the past 12 months, the treatment landscape for patients with non–small cell lung cancer has expanded dramatically with FDA approvals of the first drugs directed at KRAS G12C and EGFR exon 20 mutations as well as continued progress in developing new therapies for subsets of patients with other molecularly targetable alterations and with PD-L1–high disease.

Raajit K. Rampal, MD, PhD, discusses symptom management in patients with myelofibrosis, defining disease progression, and key considerations for starting or delaying treatment.

Data presented during the 2021 ASCO Annual Meeting offered insight into the optimization of BTK inhibitors, induction therapy, consolidative therapy, and radiation therapy for patients across the paradigm of hematologic malignancies.

Dose-dependent engraftment of the investigative CAR T-cell therapy CYAD-211 was demonstrated in the first patient with relapsed/refractory multiple myeloma to receive this dose in the phase 1 IMMUNICY-1 trial, and no graft-versus-host disease has been reported to date.

The addition of venetoclax to lenalidomide and rituximab resulted in a high response rate and encouraging minimal residual disease undetectability in patients with newly diagnosed mantle cell lymphoma—even in those with high-risk features.

R. Lor Randall, MD, FACS, discusses the advantages of rotationplasty for oncologic and non-oncologic indications in children and young adults.

A new prognostic tool, the nomogram, has demonstrated the ability to predict outcomes following treatment with lutetium-177 prostate-specific membrane antigen in patients with metastatic castration-resistant prostate cancer, and could potentially be used to inform future trial designs and clinical decisions.

Completion of treatment options such as surgery, chemotherapy, and radiation within 38 weeks from a diagnosis with breast cancer was associated with improved survival in this population.

Mark E. Sherman, MD, discusses research efforts evaluating immune responses and risk of TNBC and implications for higher rates of disease among African American women.

An expert of panelists provide an overview of TA-TMA, including findings that raise suspicion of this complication, strategies they use for making the diagnosis, and how they intervene given limited treatment options.

The FDA has granted a regular approval to pembrolizumab plus lenvatinib for the treatment of patients with advanced endometrial carcinoma that is not microsatellite instability high or mismatch repair deficient, who have disease progression after previous systemic therapy in any setting, and who are not candidates for curative surgery or radiation.

Mitchell R. Smith, MD, PhD, discusses the results of the ECOG-ACRIN E1411 trial examining BR-based induction treatment in patients with mantle cell lymphoma and next steps for research.

Repetitive locoregional infusion of HER2-specific CAR T cells did not induce any dose-limiting toxicities.

Stacey A. Cohen MD, discusses the preliminary results of the ongoing GALAXY trial, part of the CIRCULATE-Japan project, in colorectal cancer.

William Gradishar, MD, discusses the significance of drug development in HER2-positive breast cancer.

The FDA has granted an orphan drug designation to alrizomadlin as a potential therapeutic option for patients with stage IIB-IV melanoma.

The safety and efficacy of the oral MDM2 inhibitor milademetan is under investigation vs trabectedin, a current standard of care, in the treatment of patients with dedifferentiated liposarcoma as part of the recently initiated phase 3 MANTRA trial.